A New Framework for Assessing Digital Health Technologies
By Staff Writer
October 23, 2023
The Importance of Developing a Brand-New Structure
The field of digital health technologies (DHTs), which offers novel solutions for the delivery of healthcare, is undergoing rapid development. However, doing an evaluation of their usefulness presents a novel obstacle due to the fact that conventional frameworks for health technology such as pharmaceuticals and medical equipment cannot be directly applied to them. The Peterson Health Technology Institute (PHTI) has established a value assessment framework to guide evaluations of digital health technologies (DHTs), with the goals of creating evidentiary standards for technology developers and assisting organisations in adopting impactful DHTs. This methodology is illustrated below.
The Framework of the Peterson Health Technology Institute
The evaluation of the value of DHTs must pay close attention to the ways in which they affect the economy. DHTs are projected to improve care outcomes while simultaneously reducing overall costs, or give dramatically improved access at significantly cheaper costs than other options. This is in contrast to new medications, which often increase the cost to the health system. Because of the one-of-a-kind characteristics of DHTs, the PHTI paradigm places a greater emphasis on cost-effectiveness analysis over long-term cost-benefit analysis.
The methodology also takes into account the larger economic benefits of DHTs, such as increases in productivity as well as decreases in the amount of time as well as money spent by families and caregivers. However, these advantages will not be considered in the major study of how the budget would be impacted.
Digital Health Technologies
The PHTI’s approach for evaluating DHTs is a significant step towards standardising the evaluation of these technologies and marks an important step in that direction. The framework will guide technology developers in their product development by defining clear and thorough criteria of evidence, and it will assist healthcare organisations in making educated decisions about using DHTs.
The PHTI’s framework will, in the end, contribute to improved health outcomes as well as cost savings in the healthcare sector. This will be accomplished by guaranteeing that only the DHTs that are the most effective and cost-efficient will be adopted.
🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?
Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.
Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.
🌟 How can personalized medicine transform breast cancer treatment in Spain?
The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.
Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.
🌟 Are we on the brink of transforming breast cancer treatment?
NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.
Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.
